Clinical Trial

Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

Study acronym: POTAMI
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
Trial Details
NCT Number NCT06742567
Lead Sponsor National Institute of Cardiovascular Diseases, Pakistan
Conditions Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus, Prophylaxis
Enrollment 472 participants
Start Date 2024-12-02
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-19